源自中草药的自然抗癌化合物研究进展综述
本综述系统检索PubMed等数据库,汇总2011年以来中草药来源抗癌化合物(如姜黄素、表没食子儿茶素没食子酸酯、小檗碱、青蒿素、人参皂苷Rg3等)的体外与体内抗癌活性、新作用机制、相关临床研究及联合治疗与免疫调节中的创新应用,并指出免疫调节效应与临床试验证据仍很有限,需进一步研究其作为免疫检查点调节剂的作用。
要点
- 中草药来源化合物具有抗增殖、促凋亡、抗转移、抗血管生成及调节自噬、逆转多药耐药等抗癌活性。
- 部分化合物可平衡免疫、增强化疗效果,但免疫调节效应与临床试验证据有限。
- 需进一步研究这些化合物作为免疫检查点调节剂的作用机制。
核心结论
- 中草药来源的多种天然化合物在体外和体内显示抗癌活性,但免疫调节效应与临床试验证据仍很有限,需进一步研究其作为免疫检查点调节剂的作用机制。
研究设计与样本
- 系统综述,检索PubMed、Web of Science、Medline、Scopus和Clinical Trials数据库,汇总2011年以来报道的中草药来源抗癌关键化合物。
主要发现
- 姜黄素、表没食子儿茶素没食子酸酯、小檗碱、青蒿素、人参皂苷Rg3、熊果酸、水飞蓟宾、大黄素、雷公藤甲素、葫芦素B、丹参酮I、冬凌草甲素、紫草素、藤黄酸、青蒿琥酯、汉黄芩素、β-榄香烯和千金藤素等具有抗癌活性。
- 上述化合物在体外和体内表现出抗增殖、促凋亡、抗转移、抗血管生成、调节自噬、逆转多药耐药、平衡免疫和增强化疗等效应。
- 综述还描述了双氢青蒿素、人参皂苷Rh2、化合物K、葫芦素D、E、I、丹参酮IIA和隐丹参酮等有前景化合物的潜力。
临床怎么用
- 关注中草药来源抗癌化合物在联合治疗和免疫调节中的创新应用,但免疫调节效应与临床试验证据有限。
局限性
- 关于中草药来源天然抗癌化合物的免疫调节效应和临床试验证据非常有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Numerous natural products originated from Chinese herbal medicine exhibit anti-cancer activities, including anti-proliferative, pro-apoptotic, anti-metastatic, anti-angiogenic effects, as well as regulate autophagy, reverse multidrug resistance, balance immunity, and enhance chemotherapy in vitro and in vivo. To provide new insights into the critical path ahead, we systemically reviewed the most recent advances (reported since 2011) on the key compounds with anti-cancer effects derived from Chinese herbal medicine (curcumin, epigallocatechin gallate, berberine, artemisinin, ginsenoside Rg3, ursolic acid, silibinin, emodin, triptolide, cucurbitacin B, tanshinone I, oridonin, shikonin, gambogic acid, artesunate, wogonin, β-elemene, and cepharanthine) in scientific databases (PubMed, Web of Science, Medline, Scopus, and Clinical Trials). With a broader perspective, we focused on their recently discovered and/or investigated pharmacological effects, novel mechanism of action, relevant clinical studies, and their innovative applications in combined therapy and immunomodulation. In addition, the present review has extended to describe other promising compounds including dihydroartemisinin, ginsenoside Rh2, compound K, cucurbitacins D, E, I, tanshinone IIA and cryptotanshinone in view of their potentials in cancer therapy. Up to now, the evidence about the immunomodulatory effects and clinical trials of natural anti-cancer compounds from Chinese herbal medicine is very limited, and further research is needed to monitor their immunoregulatory effects and explore their mechanisms of action as modulators of immune checkpoints.
引用
- Luo H, Vong CT, Chen H, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med. 2019. PMID: 31719837. doi:10.1186/s13020-019-0270-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。